← All trials
NCT05522335
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2022
- Primary completion
- Jul 19, 2022
- Completion date
- Feb 28, 2023
- First posted
- Aug 31, 2022
- Last posted
- Aug 31, 2022
- Enrollment
- 3160
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bharat Biotech International LimitedLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.